{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:25:38Z","timestamp":1789230338955,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vph.2021.106863","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T07:30:59Z","timestamp":1618558259000},"page":"106863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus"],"prefix":"10.1016","volume":"140","author":[{"given":"Ingrid","family":"Yao Mattisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rattik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Bj\u00f6rkbacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Ljungcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Terrinoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Holmgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla Nordin","family":"Fredrikson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Gullstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders A.","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wigren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2021.106863_bb0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2021.106863_bb0010","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.immuni.2013.06.009","article-title":"Immune effector mechanisms implicated in atherosclerosis: from mice to humans","volume":"38","author":"Libby","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.vph.2021.106863_bb0015","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2021.106863_bb0020","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/01.CIR.95.4.1062","article-title":"Oxidative modification of LDL and atherogenesis","volume":"95","author":"Steinberg","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2021.106863_bb0025","doi-asserted-by":"crossref","first-page":"12893","DOI":"10.1074\/jbc.273.21.12893","article-title":"Potential role for ceramide in mitogen-activated protein kinase activation and proliferation of vascular smooth muscle cells induced by oxidized low density lipoprotein","volume":"273","author":"Auge","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2021.106863_bb0030","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(02)01201-1","article-title":"Pattern recognition receptors: doubling up for the innate immune response","volume":"111","author":"Gordon","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.vph.2021.106863_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1172\/JCI63108","article-title":"Adaptive immunity in atherogenesis: new insights and therapeutic approaches","volume":"123","author":"Lichtman","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2021.106863_bb0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.vph.2021.106863_bb0045","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/joim.12353","article-title":"Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges","volume":"278","author":"Nilsson","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.vph.2021.106863_bb0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tcm.2007.03.001","article-title":"Regulatory T-cell immunity in atherosclerosis","volume":"17","author":"Mallat","year":"2007","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.vph.2021.106863_bb0055","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/nm1102-1218","article-title":"Innate and acquired immunity in atherogenesis","volume":"8","author":"Binder","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2021.106863_bb0060","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/ATVBAHA.111.242800","article-title":"Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice","volume":"32","author":"Herbin","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2021.106863_bb0065","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.ATV.0000067937.93716.DB","article-title":"Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences","volume":"23","author":"Fredrikson","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2021.106863_bb0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2004.04.016","article-title":"Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (\u2212\/\u2212) mice","volume":"176","author":"Chyu","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2021.106863_bb0075","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fimmu.2013.00493","article-title":"Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100","volume":"4","author":"Tse","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vph.2021.106863_bb0080","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/01.CIR.0000143162.56057.B5","article-title":"Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis","volume":"110","author":"Schiopu","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2021.106863_bb0085","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2021.106863_bb0090","series-title":"Systemic Lupus Erythematosus: A Review of Disease and Treatment Options","first-page":"110","volume":"28","author":"Gurevitz","year":"2013"},{"key":"10.1016\/j.vph.2021.106863_bb0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-med-060911-090007","article-title":"Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus","volume":"64","author":"Kahlenberg","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.vph.2021.106863_bb0100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/BOR.0000000000000528","article-title":"Cardiovascular disease in systemic lupus erythematosus: an update","volume":"30","author":"Liu","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.vph.2021.106863_bb0105","series-title":"Traditional Framingham Risk Factors Fail to Fully Account for Accelerated Atherosclerosis in Systemic Lupus Erythematosus","first-page":"295","volume":"44","author":"Esdaile","year":"2001"},{"key":"10.1016\/j.vph.2021.106863_bb0110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/ar3206","article-title":"Disturbances of apoptotic cell clearance in systemic lupus erythematosus","volume":"13","author":"Shao","year":"2011","journal-title":"Arthrit. Res. Ther."},{"key":"10.1016\/j.vph.2021.106863_bb0115","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/joim.12357","article-title":"Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention","volume":"278","author":"Wigren","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.vph.2021.106863_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.01.022","article-title":"Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis","volume":"270","author":"Wigren","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2021.106863_bb0125","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/CIRCULATIONAHA.106.662080","article-title":"Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice","volume":"115","author":"Ait-Oufella","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2021.106863_bb0130","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.cmet.2009.03.003","article-title":"Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe\u2212\/\u2212 and Ldlr\u2212\/\u2212 mice lacking CHOP","volume":"9","author":"Thorp","year":"2009","journal-title":"Cell Metab."},{"key":"10.1016\/j.vph.2021.106863_bb0135","series-title":"Impaired Clearance of Apoptotic Cells Promotes Synergy Between Atherogenesis and Autoimmune Disease","first-page":"1121","volume":"199","author":"Aprahamian","year":"2004"},{"key":"10.1016\/j.vph.2021.106863_bb0140","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/01.CIR.0000143162.56057.B5","article-title":"Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis","volume":"110","author":"Schiopu","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2021.106863_bb0145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/cei.12651","article-title":"Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus","volume":"181","author":"Svenungsson","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.vph.2021.106863_bb0150","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.vph.2021.106863_bb0155","first-page":"373","article-title":"The Systemic Lupus International Collaborating Clinics\/American College of Rheumatology (SLICC\/ACR) damage index for systemic lupus erythematosus international comparison","volume":"27","author":"Gladman","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.vph.2021.106863_bb0160","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/BOR.0000000000000083","article-title":"Beyond apoptosis in lupus","volume":"26","author":"Colonna","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.vph.2021.106863_bb0165","series-title":"Mucosal Immunity and Vaccines","first-page":"S45","volume":"11","author":"Holmgren","year":"2005"},{"key":"10.1016\/j.vph.2021.106863_bb0170","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2796.2008.01959.x","article-title":"Introduction: atherosclerosis as inflammation: a controversial concept becomes accepted","volume":"263","author":"Hansson","year":"2008","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.vph.2021.106863_bb0175","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s13075-016-1204-x","article-title":"Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis","volume":"18","author":"Park","year":"2016","journal-title":"Arthrit. Res. Ther."},{"key":"10.1016\/j.vph.2021.106863_bb0180","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1194\/jlr.M600512-JLR200","article-title":"ApoE\u2212\/-Fas\u2212\/\u2212 C57BL\/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia","volume":"48","author":"Feng","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.vph.2021.106863_bb0185","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clim.2008.01.002","article-title":"Accelerated atherosclerosis in ApoE deficient lupus mouse models","volume":"127","author":"Ma","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.vph.2021.106863_bb0190","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.1073\/pnas.93.14.7196","article-title":"Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit","volume":"93","author":"Sun","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.vph.2021.106863_bb0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2249.2004.02520.x","article-title":"Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet\u2019s disease","volume":"137","author":"Stanford","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.vph.2021.106863_bb0200","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.atherosclerosis.2010.06.007","article-title":"Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her\/J mice","volume":"212","author":"Lu","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2021.106863_bb0205","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1161\/CIRCULATIONAHA.106.615609","article-title":"Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis","volume":"114","author":"van Puijvelde","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2021.106863_bb0210","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/ATVBAHA.109.202671","article-title":"Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis","volume":"30","author":"Klingenberg","year":"2010","journal-title":"ATVB"},{"key":"10.1016\/j.vph.2021.106863_bb0215","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm1343","article-title":"Natural regulatory T cells control the development of atherosclerosis in mice","volume":"12","author":"Ait-Oufella","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2021.106863_bb0220","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1161\/ATVBAHA.112.251579","article-title":"Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke","volume":"32","author":"Wigren","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2021.106863_bb0225","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.atherosclerosis.2006.03.032","article-title":"Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100","volume":"190","author":"Strom","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2021.106863_bb0230","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.jacc.2007.07.081","article-title":"Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(\u2212\/\u2212)\/low-density lipoprotein receptor(\u2212\/\u2212) mice","volume":"50","author":"Schiopu","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2021.106863_bb0235","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ard.2005.037143","article-title":"Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells","volume":"65","author":"Tas","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vph.2021.106863_bb0240","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.molmet.2013.06.001","article-title":"Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques","volume":"2","author":"Li","year":"2013","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.vph.2021.106863_bb0245","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jcmg.2014.06.021","article-title":"FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity","volume":"8","author":"Lehrer-Graiwer","year":"2015","journal-title":"J. Am. Coll. Cardiol. Img."},{"key":"10.1016\/j.vph.2021.106863_bb0250","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.10130","article-title":"Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo","volume":"46","author":"Gharavi","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2021.106863_bb0255","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1191\/096120399678847434","article-title":"Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE","volume":"8","author":"Wu","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.vph.2021.106863_bb0260","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nri.2016.63","article-title":"Innate sensing of oxidation-specific epitopes in health and disease","volume":"16","author":"Binder","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.vph.2021.106863_bb0265","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/ATVBAHA.115.306938","article-title":"Low levels of apolipoprotein B-100 autoantibodies are associated with increased risk of coronary events","volume":"36","author":"Bjorkbacka","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189121000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189121000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:20:16Z","timestamp":1761528016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189121000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":53,"alternative-id":["S1537189121000355"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2021.106863","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2021.106863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106863"}}